BioInvent 和 Transgene 报告称，默克 KEYTRUDA 对 BT-001 溶瘤病毒的 1/2a 期试验结果令人鼓舞，显示出良好的安全性和更高的反应率。 BioInvent and Transgene report encouraging Phase 1/2a trial results for BT-001 oncolytic virus with Merck's KEYTRUDA, showing a favorable safety profile and improved response rates.
BioInvent 和 Transgene 报告了令人鼓舞的 BT-001 早期 1/2a 期试验结果，BT-001 是一种溶瘤病毒，与默克的 KEYTRUDA（帕博利珠单抗）联合使用。 BioInvent and Transgene reported encouraging early Phase 1/2a trial results for BT-001, an oncolytic virus combined with Merck's KEYTRUDA (pembrolizumab). 该疗法显示出一种有利的安全特征,没有剂量限制毒性。 The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities. 在单一疗法中,18名病人中有4名表现出稳定的疾病,6名病人中有2名在与pembrocolizumab相结合时得到部分反应。 In monotherapy, 4 of 18 patients showed stable disease, while 2 of 6 patients had partial responses when combined with pembrolizumab. 结果将在2024年9月的ESMO年会上发表. Findings will be presented at the ESMO Annual Meeting in September 2024.